172 related articles for article (PubMed ID: 28395444)
21. Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Fan S; Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
Front Oncol; 2021; 11():773394. PubMed ID: 35070977
[TBL] [Abstract][Full Text] [Related]
22. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
[TBL] [Abstract][Full Text] [Related]
23. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
24. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
Zhou W; Chen G; Gong D; Gao Y; Yu L
Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
[TBL] [Abstract][Full Text] [Related]
26. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890
[No Abstract] [Full Text] [Related]
27. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
28. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
[TBL] [Abstract][Full Text] [Related]
29. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
Zhu HH; Zhang XH; Qin YZ; Liu DH; Jiang H; Chen H; Jiang Q; Xu LP; Lu J; Han W; Bao L; Wang Y; Chen YH; Wang JZ; Wang FR; Lai YY; Chai JY; Wang LR; Liu YR; Liu KY; Jiang B; Huang XJ
Blood; 2013 May; 121(20):4056-62. PubMed ID: 23535063
[TBL] [Abstract][Full Text] [Related]
30. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
31. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
[TBL] [Abstract][Full Text] [Related]
32. [An interlaboratory comparison study on the detection of RUNX1-RUNX1T1 fusion transcript levels and WT1 transcript levels].
Qin YZ; Zhu LW; Lin S; Geng SX; Liu SW; Cheng H; Wu CY; Xiao M; Li XQ; Hu RP; Wang LL; Liu HY; Ma DX; Guan T; Ye YX; Niu T; Cen JN; Lu LS; Sun L; Yang TH; Wang YG; Li T; Wang Y; Li QH; Zhao XS; Li LD; Chen WM; Long LY; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):889-894. PubMed ID: 31856435
[No Abstract] [Full Text] [Related]
33. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.
Ahmed S; Elsherif M; Yassin D; Elsharkawy N; Mohamed AS; Yasser N; Elnashar A; Hafez H; Kolb EA; Elhaddad A
Front Oncol; 2024; 14():1340909. PubMed ID: 38720804
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).
Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y
Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269
[TBL] [Abstract][Full Text] [Related]
35. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
36. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
Ommen HB; Ostergaard M; Yan M; Braendstrup K; Zhang DE; Hokland P
Eur J Haematol; 2010 Feb; 84(2):128-32. PubMed ID: 19891700
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
[TBL] [Abstract][Full Text] [Related]
38. [Expression of CD19 and CD56 in AML Patients with RUNX1-RUNX1T1 Mutation and Its Clinical Significance].
Hu ZL; Zhang F; Huang BJ; Pan SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):727-732. PubMed ID: 29950211
[TBL] [Abstract][Full Text] [Related]
39. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
Zampini M; Tregnago C; Bisio V; Simula L; Borella G; Manara E; Zanon C; Zonta F; Serafin V; Accordi B; Campello S; Buldini B; Pession A; Locatelli F; Basso G; Pigazzi M
Leukemia; 2018 May; 32(5):1124-1134. PubMed ID: 29472719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]